Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Jill Corre, Laurent Voillat et al.|Blood|2022Cited by 64
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresTitouan Cazaubiel, Jill Corre, Xavier Leleu et al.|Blood|2022Cited by 30
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Aurore Perrot et al.|Blood|2025Cited by 15
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple MyelomaThomas Chalopin, Salomon Manier, Hélène Demarquette et al.|Blood|2024Cited by 3
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Blood Cancer Journal|2025Cited by 2